# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jim Thorpe (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML011-SYN
- Date: 2026-09-21
- Fictional facility: St. Posthumous Health Center
- Fictional author: Nolan Fairbanks, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Coronary disease review in cardiac rehabilitation, lipid recheck, and lip surveillance. **S**

## History of present illness

Mr. Thorpe returns ten weeks after ezetimibe was added. He has done 18 cardiac rehabilitation sessions and now walks up the hill to the ball field without stopping. He has had no angina and no nitroglycerin since early summer. The back strain from four weeks ago settled within ten days on acetaminophen, and he is back to full sessions. He uses lip balm with sunscreen and a hat every day. He has no new sore on his lips or in his mouth and no lumps in his neck. **S**

| Element | Detail |
|---|---|
| Cardiac rehabilitation | 18 sessions; walks uphill without stopping |
| Angina | None since early summer |
| Back strain | Resolved within ten days |
| Lip | No new sore; no neck lumps |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Ears, nose, mouth, and throat | Negative | No lip or mouth sores; no hoarseness |
| Cardiovascular | Negative | No chest tightness, palpitations, or leg swelling |
| Musculoskeletal | Negative | Back pain resolved; no muscle aches |

3 systems reviewed. **S**

## Current medications

- Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily **S**
- Atorvastatin 80 mg oral tablet, one tablet by mouth daily **S**
- Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily **S**
- Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue for chest pain, repeated every 5 minutes up to 3 tablets **S**
- Ezetimibe 10 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/76 mmHg; pulse 60 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 91.6 kg; BMI 26.8 kg/m². All vital signs are synthetic.

Total cholesterol: 118 mg/dL; LDL cholesterol: 51 mg/dL; HDL cholesterol: 44 mg/dL; Triglycerides: 115 mg/dL. All results are synthetic.

## Change since baseline

- Total cholesterol: 238 mg/dL (high) at baseline, 118 mg/dL at this visit **S**
- LDL cholesterol: 158 mg/dL (high) at baseline, 51 mg/dL at this visit **S**
- HDL cholesterol: 38 mg/dL (low) at baseline, 44 mg/dL at this visit **S**
- Triglycerides: 210 mg/dL (high) at baseline, 115 mg/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 124/76, pulse 60; weight 91.6 kg |
| Head and neck | Lip scar mature and soft; no nodularity or new lesion; mouth normal; no neck nodes |
| Back | Full, painless range of motion |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Chronic coronary disease with stable angina** (I25.119). No angina on medical therapy and cardiac rehabilitation; blood pressure 124/76, at goal. LDL 51 mg/dL on atorvastatin and ezetimibe, at the goal of below 55 mg/dL; total cholesterol 118, HDL 44, triglycerides 115 mg/dL. Weight down 2.4 kg. **S**
   - Continue aspirin, atorvastatin 80 mg, ezetimibe 10 mg and metoprolol succinate 25 mg.
   - Finish the 36 rehabilitation sessions, then a home exercise plan.
   - Lipid panel in 6 to 12 months.
2. **Acute low back strain** (S39.012A). Resolved. **S**
   - Lift with the legs; ask a player to help with heavy bags.
3. **Squamous cell carcinoma of the left lower lip, excised** (C00.1). No sign of recurrence about twelve weeks after excision. **S**
   - Next lip, mouth and neck examination in about five weeks.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Examination of the lips, mouth, and neck | Every 1 to 3 months in year 1, 2 to 6 months in year 2, 4 to 8 months in years 3 to 5, then yearly | Completed today | No recurrence or new lesion; no neck nodes |
| Self-management | Sun protection of the lips and skin | Every visit | Completed today | Lip balm with sunscreen and a hat daily |
| Self-management | Tobacco and alcohol use | Every visit | Completed today | Tobacco-free |
| Referral | Dental evaluation | After diagnosis, then routine | Due | Not yet arranged; he is deciding where to go |
| Examination | Blood pressure (goal below 130/80) | Every visit | Completed today | 124/76, at goal |
| Examination | Weight, BMI, and physical activity | Every visit | Completed today | 91.6 kg, BMI 26.8; rehabilitation three times a week |
| Survey | Angina frequency and nitroglycerin use | Every visit | Completed today | None; no nitroglycerin |
| Medication safety | Adherence and side effects: aspirin, high-intensity statin, beta-blocker | Every visit | Completed today | All taken daily, with ezetimibe; no side effects |
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing lipid therapy, then every 3 to 12 months; goal LDL below 55 mg/dL | Completed today | Ten weeks after adding ezetimibe: total cholesterol 118, LDL 51, HDL 44, triglycerides 115 mg/dL; at goal |
| Referral | Cardiac rehabilitation | After a heart attack or for stable angina: up to 36 sessions | Completed today | 18 of 36 sessions |
| Survey | Depression screen (PHQ-2 or PHQ-9) | Yearly | Up to date | PHQ-2 1 at intake; next at the preventive visit |

## Goal progress

- Lip cancer removed with clear margins and no recurrence on surveillance through four months. In progress; target 2026-10-26. **S**
- LDL cholesterol below 55 mg/dL on secondary prevention. Outcome by 2026-09-21: LDL 51 mg/dL on atorvastatin 80 mg and ezetimibe 10 mg. **S**
- Blood pressure below 130/80 mmHg. Outcome by 2026-09-21: 124/76 on metoprolol. **S**
- Complete cardiac rehabilitation and walk uphill without angina. In progress; target 2026-10-26. **S**
- Stay tobacco-free and protect his lips and skin from the sun. In progress; target 2026-10-26. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers (cancer of the lip and oral cavity) (2026), National Comprehensive Cancer Network
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation)
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018), American Heart Association and American College of Cardiology (Circulation)
- CMID: Clinical Monitoring Intelligence Database, ischemic heart disease monograph (2026), Aether Forge

## Follow-up

- Preventive visit in two weeks. Lip surveillance and coronary disease review in about five weeks. **S**
- Next scheduled visit 2026-10-05: periodic adult preventive visit. **S**
